Roche expands Tecentriq label and Roche Holding stock costs EUR 387.63

Published on 10/12/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ATOMIC cut recurrence risk by 50.00 percent in stage III cancer. Roche Holding stock costs EUR 387.63 on October 12, 2026, while core EPS rose 11.00 percent in 2025.

Key points in brief

Roche expanded Tecentriq to a twelfth US indication for stage III dMMR colon cancer on October 9, 2026.
The ATOMIC study showed a 50.00 percent reduction in recurrence or death risk versus chemotherapy alone.
Roche Holding stock was at EUR 387.63 at Lang & Schwarz on October 12, 2026 at 9:53 a.m. CEST.
Roche will present third-quarter 2026 sales on October 22, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (CH1499059983) was at EUR 387.63 at Lang & Schwarz on October 12, 2026 at 9:53 a.m. CEST as the group’s Tecentriq cancer franchise gained a new US use. On October 9, 2026, Roche reported FDA approval for Tecentriq and Tecentriq Hybreza with chemotherapy in stage III deficient DNA mismatch repair colon cancer.

FDA approval adds a twelfth indication

The approval is Tecentriq’s twelfth US indication and covers treatment with a fluoropyrimidine and oxaliplatin after surgery. The ATOMIC phase III study enrolled 712 patients and showed a 50.00 percent reduction in the risk of recurrence or death versus chemotherapy alone, with 36-month disease-free survival at 86.00 percent compared with 76.00 percent.

The commercial significance is specific rather than broad: the label targets a biomarker-defined group, while Roche is pursuing further regulatory filings in Europe. That creates a new use for an established medicine, but uptake remains tied to mismatch repair testing and the eligible patient population.

Half-year sales fell 2.00 percent

Roche’s first-half 2026 sales were CHF 30.364 billion, down 2.00 percent from CHF 30.944 billion in the same period a year earlier, while IFRS operating profit fell 1.00 percent to CHF 9.671 billion. VCBeat reported net profit attributable to shareholders of CHF 6.871 billion for the period.

The contrast matters for the stock narrative. The FDA decision adds a measurable pipeline and label catalyst, while the latest half-year sales base still showed a 2.00 percent year-over-year decline. Roche’s 2025 core earnings per share grew 11.00 percent at constant exchange rates to CHF 19.46, according to Roche.

What comes on October 22?

Roche’s next scheduled company date is October 22, 2026, when it will present third-quarter sales at 2:00 p.m. CEST. The investor calendar also lists the Berenberg Pharma CFO Series on November 2, 2026 at 3:00 p.m. CET, both dates published by Roche.

Analyst target remains CHF 340

Deutsche Bank Research kept Roche at Hold with a CHF 340 price target in an analysis first distributed on September 29, 2026, according to FinanzNachrichten.de. The target provides a counterweight to the regulatory news because it reflects a neutral stance despite the new indication.

Roche Holding stock at EUR 387.63

Roche Holding stock was trading at EUR 387.63 at Lang & Schwarz on October 12, 2026 at 9:53 a.m. CEST. The primary listing is the participation certificate on SIX Swiss Exchange, where Roche identifies the ticker as ROP. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.